Replicor Press Release 2019年3月1日

StephenW

Replicor Press Release March 1, 2019


Media contact:
Natasha Dorjet
[email protected]
514-733-1998



Replicor will provide data on the beneficial effects of transaminase flares on HBV functional cure at the 2019 EASL / AASLD endpoint meeting

Montreal, March 1, 2019 - Replicor Inc., a privately held biopharmaceutical company with the goal of treating patients with chronic hepatitis B and D, announced today that it will provide data showing that transaminase achieves HBV function in 2019 during treatment The beneficial effects of the cure EASL / AASLD HBV endpoint meeting will be held in London, England from March 8th to 9th, 2019.

This analysis (presented as poster P03-01 on March 8) utilizes the entire enrolled patient population from REP 301 (NCT02233075) and REP 401 (NCT02565719) studies and evaluates the transaminase flare observed during REP 2139-based combination therapy. And their effects on liver function. In addition, the effects of baseline and response parameters on the appearance of transaminase flares and their association with functional healing were also assessed.

Other presentations on March 8th and 9th will provide the latest mechanical data from REP 2139 and the post-treatment response in the ongoing REP 401 protocol.

The reproducer presentation of the 2019 EASL / AASLD HBV Endpoint Conference will be posted on the company's website and posted at www.replicor.com/science/conference-presentations. For more information on the 2019 EASL / AASLD HBV Endpoint Conference, please visit: https://www.aasld.org/events-pro ... endpoints-workshop.

About Replicor

Replicor is a private biopharmaceutical company with state-of-the-art animal and human clinical data for the treatment of HBV and HDV. The company is committed to accelerating the development of effective treatment options for patients with HBV and HBV / HDV co-infection. For more information on Replicor, please visit our website at www.replicor.com.

StephenW

Replicor Press Release 2019年3月1日


媒体联系：
Natasha Dorjet
[email protected]
514-733-1998



Replicor将在2019年EASL / AASLD终点会议上提供转氨酶突发对HBV功能治愈的有益作用的数据

蒙特利尔，2019年3月1日 -  Replicor Inc.是一家私营生物制药公司，其目标是治疗慢性乙型和乙型肝炎患者，今天宣布将提供数据显示转氨酶在2019年治疗期间达到HBV功能。治疗EASL / AASLD HBV终点会议将于2019年3月8日至9日在英国伦敦举行。

该分析（在3月8日作为海报P03-01呈现）利用来自REP 301（NCT02233075）和REP 401（NCT02565719）的整个登记患者群体进行研究并评估在基于REP 2139的组合疗法期间观察到的转氨酶突发。以及它们对肝功能的影响。此外，还评估了基线和反应参数对转氨酶突发的出现及其与功能性愈合的关联的影响。

3月8日和9日的其他演讲将提供REP 2139的最新机械数据和正在进行的REP 401协议中的治疗后响应。

2019年EASL / AASLD HBV端点会议的复制者演示文稿将发布在公司网站上，并发布在www.replicor.com/science/conference-presentations上。有关2019年EASL / AASLD HBV端点会议的更多信息，请访问：https：//www.aasld.org/events-professional-development/easl-aasld-hbv-treatment-endpoints-workshop。

关于Replicor

Replicor是一家私营生物制药公司，拥有最先进的动物和人类临床数据，用于治疗HBV和HDV。该公司致力于加速为HBV和HBV / HDV合并感染患者开发有效的治疗方案。有关Replicor的更多信息，请访问我们的网站www.replicor.com。

齐欢畅